Epigenetic Regulation in Melanoma: Facts and Hopes
Abstract
:1. Introduction
2. Materials and Methods
3. Epigenetic Regulation and Melanoma
3.1. DNA Methylation Status
3.2. Chromatin Remodeling
3.3. Non-Coding RNA Regulation
4. Targeting Epigenetic Machinery in Melanoma
4.1. Immunotherapy
4.2. Targeted Therapy
4.3. Chemotherapy/Radiotherapy
5. Future Directions and Conclusions
Author Contributions
Funding
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Melanoma|Cancer.Net. Available online: https://www.cancer.net/cancer-types/melanoma/statistics (accessed on 11 June 2021).
- Leonardi, G.C.; Candido, S.; Falzone, L.; Spandidos, D.A.; Libra, M. Cutaneous melanoma and the immunotherapy revolution (Review). Int. J. Oncol. 2020, 57, 609–618. [Google Scholar] [CrossRef]
- Giunta, E.F.; De Falco, V.; Napolitano, S.; Argenziano, G.; Brancaccio, G.; Moscarella, E.; Ciardiello, D.; Ciardiello, F.; Troiani, T. Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations. Ther. Adv. Med. Oncol. 2020, 12, 1758835920925219. [Google Scholar] [CrossRef]
- Pham, D.D.M.; Guhan, S.; Tsao, H. KIT and melanoma: Biological insights and clinical implications. Yonsei Med. J. 2020, 61, 562–571. [Google Scholar] [CrossRef] [PubMed]
- Muñoz-Couselo, E.; Adelantado, E.Z.; Vélez, C.O.; Soberino-García, J.; Perez-Garcia, J.M. NRAS-mutant melanoma: Current challenges and future prospect. OncoTargets Ther. 2017, 10, 3941–3947. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Michielin, O.; Atkins, M.B.; Koon, H.B.; Dummer, R.; Ascierto, P.A. Evolving impact of long-term survival results on metastatic melanoma treatment. J. Immunother. Cancer 2020, 8, e000948. [Google Scholar] [CrossRef] [PubMed]
- Winder, M.; Virós, A. Mechanisms of Drug Resistance in Melanoma. Handb. Exp. Pharmacol. 2018, 249, 91–108. [Google Scholar]
- Feinberg, A.P.; Tycko, B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4, 143–153. [Google Scholar] [CrossRef]
- Feinberg, A.; Koldobskiy, A.P.F.M.A.; Göndör, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 2016, 17, 284–299. [Google Scholar] [CrossRef] [PubMed]
- Jin, B.; Li, Y.; Robertson, K.D. DNA methylation: Superior or subordinate in the epigenetic hierarchy? Genes Cancer 2011, 2, 607–617. [Google Scholar] [CrossRef] [Green Version]
- Deaton, A.; Bird, A. CpG islands and the regulation of transcription. Genes Dev. 2011, 25, 1010–1022. [Google Scholar] [CrossRef] [Green Version]
- Feinberg, A.; Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nat. Cell Biol. 1983, 301, 89–92. [Google Scholar] [CrossRef]
- Kim, Y.-I.; Giuliano, A.; Hatch, K.D.; Schneider, A.; Nour, M.A.; Dallal, G.E.; Selhub, J.; Mason, J.B. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer 1994, 74, 893–899. [Google Scholar] [CrossRef]
- Cravo, M.; Pinto, R.; Fidalgo, P.; Chaves, P.; Gloria, L.; Nobre-Leitao, C.; Mira, F.C. Global DNA hypomethylation occurs in the early stages of intestinal type gastric carcinoma. Gut 1996, 39, 434–438. [Google Scholar] [CrossRef] [Green Version]
- Soares, J.; E Pinto, A.; Cunha, C.V.; André, S.; Barão, I.; Sousa, J.M.; Cravo, M. Global DNA hypomethylation in breast carcinoma: Correlation with prognostic factors and tumor progression. Cancer 1999, 85, 112–118. [Google Scholar] [CrossRef]
- Ehrlich, M. DNA hypomethylation in cancer cells. Epigenomics 2009, 1, 239–259. [Google Scholar] [CrossRef] [Green Version]
- Karpf, A.R.; Matsui, S.-I. Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res. 2005, 65, 8635–8639. [Google Scholar] [CrossRef] [Green Version]
- Nakayama, M.; Wada, M.; Harada, T.; Nagayama, J.; Kusaba, H.; Ohshima, K.; Kozuru, M.; Komatsu, H.; Ueda, R.; Kuwano, M. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 1998, 92, 4296–4307. [Google Scholar] [CrossRef]
- Fraga, M.; Herranz, M.; Espada, J.; Ballestar, E.; Paz, M.F.; Ropero, S.; Erkek, E.; Bozdogan, O.; Peinado, H.; Niveleau, A.; et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res. 2004, 64, 5527–5534. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Toyota, M.; Ahuja, N.; Ohe-Toyota, M.; Herman, J.G.; Baylin, S.B.; Issa, J.-P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 1999, 96, 8681–8686. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tanemura, A.; Terando, A.M.; Sim, M.-S.; Van Hoesel, A.Q.; De Maat, M.F.; Morton, D.L.; Hoon, D.S. CpG island methylator phenotype predicts progression of malignant melanoma. Clin. Cancer Res. 2009, 15, 1801–1807. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hughes, L.A.; Melotte, V.; de Schrijver, J.; de Maat, M.; Smit, V.T.; Bovée, J.V.; French, P.J.; Brandt, P.A.V.D.; Schouten, L.J.; de Meyer, T.; et al. The CpG island methylator phenotype: What’s in a name? Cancer Res. 2013, 73, 5858–5868. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stahl, J.M.; Cheung, M.; Sharma, A.; Trivedi, N.R.; Shanmugam, S.; Robertson, G.P. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003, 63, 2881–2890. [Google Scholar]
- Mirmohammadsadegh, A.; Marini, A.; Nambiar, S.; Hassan, M.; Tannapfel, A.; Ruzicka, T.; Hengge, U.R. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006, 66, 6546–6552. [Google Scholar] [CrossRef] [Green Version]
- Lahtz, C.; Stranzenbach, R.; Fiedler, E.; Helmbold, P.; Dammann, R.H. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J. Investig. Dermatol. 2010, 130, 620–622. [Google Scholar] [CrossRef] [Green Version]
- Gonzalgo, M.L.; Bender, C.M.; You, E.H.; Glendening, J.M.; Flores, J.F.; Walker, G.J.; Hayward, N.K.; A Jones, P.; Fountain, J.W. Low frequency of p16/CDKN2A methylation in sporadic melanoma: Comparative approaches for methylation analysis of primary tumors. Cancer Res. 1997, 57, 5336–5347. [Google Scholar]
- Straume, O.; Smeds, J.; Kumar, R.; Hemminki, K.; Akslen, L.A. Significant impact of promoter hypermethylation and the 540 C > T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am. J. Pathol. 2002, 161, 229–237. [Google Scholar] [CrossRef]
- Fujimoto, A.; Morita, R.; Hatta, N.; Takehara, K.; Takata, M. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 1999, 18, 2527–2532. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jonsson, A.; Tuominen, R.; Grafström, E.; Hansson, J.; Egyhazi, S. High frequency of p16INK4A promoter methylation in NRAS-mutated cutaneous melanoma. J. Investig. Dermatol. 2010, 130, 2809–2817. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Freedberg, D.E.; Rigas, S.H.; Russak, J.; Gai, W.; Kaplow, M.; Osman, I.; Turner, F.; Randerson-Moor, J.A.; Houghton, A.; Busam, K.; et al. Frequent p16-independent inactivation of p14ARF in human melanoma. J. Natl. Cancer Inst. 2008, 100, 784–795. [Google Scholar] [CrossRef] [Green Version]
- Spugnardi, M.; Tommasi, S.; Dammann, R.; Pfeifer, G.P.; Hoon, D.S.B. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res. 2003, 63, 1639–1643. [Google Scholar] [PubMed]
- Gao, L.; Smit, M.A.; Oord, J.J.V.D.; Goeman, J.J.; Verdegaal, E.M.E.; Van Der Burg, S.H.; Stas, M.; Beck, S.; Gruis, N.A.; Tensen, C.; et al. Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma. Pigment. Cell Melanoma Res. 2013, 26, 542–554. [Google Scholar] [CrossRef]
- Tellez, C.S.; Shen, L.; Estecio, M.; Jelinek, J.; Gershenwald, J.E.; Issa, J.-P. CpG island methylation profiling in human melanoma cell lines. Melanoma Res. 2009, 19, 146–155. [Google Scholar] [CrossRef] [PubMed]
- Koga, Y.; Pelizzola, M.; Cheng, E.; Krauthammer, M.; Sznol, M.; Ariyan, S.; Narayan, D.; Molinaro, A.M.; Halaban, R.; Weissman, S.M. Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res. 2009, 19, 1462–1470. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Conway, K.; Edmiston, S.N.; Khondker, Z.S.; Groben, P.A.; Zhou, X.; Chu, H.; Kuan, P.F.; Hao, H.; Carson, C.; Berwick, M.; et al. DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment. Cell Melanoma Res. 2011, 24, 352–360. [Google Scholar] [CrossRef] [PubMed]
- Muthusamy, V.; Duraisamy, S.; Bradbury, C.M.; Hobbs, C.; Curley, D.P.; Nelson, B.; Bosenberg, M. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006, 66, 11187–11193. [Google Scholar] [CrossRef] [Green Version]
- Falahat, R.; Berglund, A.; Putney, R.M.; Perez-Villarroel, P.; Aoyama, S.; Pilon-Thomas, S.; Barber, G.N.; Mulé, J.J. Epigenetic reprogramming of tumor cell–intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. Proc. Natl. Acad. Sci. USA 2021, 118, 2013598118. [Google Scholar] [CrossRef]
- Al Emran, A.; Chatterjee, A.; Rodger, E.J.; Tiffen, J.C.; Gallagher, S.; Eccles, M.R.; Hersey, P. Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. Trends Immunol. 2019, 40, 328–344. [Google Scholar] [CrossRef] [Green Version]
- Goltz, D.; Gevensleben, H.; Vogt, T.J.; Dietrich, J.; Golletz, C.; Bootz, F.; Kristiansen, G.; Landsberg, J.; Dietrich, D. CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients. JCI Insight 2018, 3, e96793. [Google Scholar] [CrossRef] [Green Version]
- Micevic, G.; Thakral, D.; McGeary, M.; Bosenberg, M.W. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival. Pigment. Cell Melanoma Res. 2019, 32, 435–440. [Google Scholar] [CrossRef]
- Hoffmann, F.; Zarbl, R.; Niebel, D.; Sirokay, J.; Fröhlich, A.; Posch, C.; Holderried, T.A.W.; Brossart, P.; Saavedra, G.; Kuster, P.; et al. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clin. Epigenetics 2020, 12, 1–12. [Google Scholar] [CrossRef]
- Lian, C.; Xu, Y.; Ceol, C.; Wu, F.; Larson, A.; Dresser, K.; Xu, W.; Tan, L.; Hu, Y.; Zhan, Q.; et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150, 1135–1146. [Google Scholar] [CrossRef] [Green Version]
- Rasmussen, K.D.; Helin, K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016, 30, 733–750. [Google Scholar] [CrossRef] [PubMed]
- Micevic, G.; Theodosakis, N.; Bosenberg, M. Aberrant DNA methylation in melanoma: Biomarker and therapeutic opportunities. Clin. Epigenetics 2017, 9, 1–15. [Google Scholar] [CrossRef] [Green Version]
- Zhang, X.D.; Gillespie, S.K.; Borrow, J.M.; Hersey, P. The histone deacetylase inhibitor suberic bishydroxamate: A potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem. Pharmacol. 2003, 66, 1537–1545. [Google Scholar] [CrossRef]
- Bachmann, I.M.; Halvorsen, O.J.; Collett, K.; Stefansson, I.M.; Straume, O.; Haukaas, S.A.; Salvesen, H.B.; Otte, A.P.; Akslen, L.A. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 2006, 24, 268–273. [Google Scholar] [CrossRef]
- Ceol, C.J.; Houvras, Y.; Jane-Valbuena, J.; Bilodeau, S.; Orlando, D.A.; Battisti, V.; Fritsch, L.; Lin, W.M.; Hollmann, T.J.; Ferre’, F.; et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nat. Cell Biol. 2011, 471, 513–517. [Google Scholar] [CrossRef] [PubMed]
- Kato, S.; Weng, Q.Y.; Insco, M.L.; Chen, K.Y.; Muralidhar, S.; Pozniak, J.; Diaz, J.M.S.; Drier, Y.; Nguyen, N.; Lo, J.A.; et al. Gain-of-function genetic alterations of G9a drive oncogenesis. Cancer Discov. 2020, 10, 980–997. [Google Scholar] [CrossRef] [Green Version]
- Bossi, D.; Cicalese, A.; Dellino, G.I.; Luzi, L.; Riva, L.; D’Alesio, C.; Diaferia, G.R.; Carugo, A.; Cavallaro, E.; Piccioni, R.; et al. In vivo genetic screens of patient-derived tumors revealed unexpected frailty of the transformed phenotype. Cancer Discov. 2016, 6, 650–663. [Google Scholar] [CrossRef] [Green Version]
- Roesch, A.; Fukunaga-Kalabis, M.; Schmidt, E.C.; Zabierowski, S.E.; Brafford, P.A.; Vultur, A.; Basu, D.; Gimotty, P.; Vogt, T.; Herlyn, M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141, 583–594. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Segura, M.F.; Fontanals-Cirera, B.; Gaziel-Sovran, A.; Guijarro, M.V.; Hanniford, D.; Zhang, G.; González-Gomez, P.; Morante, M.; Jubierre, L.; Zhang, W.; et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 2013, 73, 6264–6276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gallagher, S.; Mijatov, B.; Gunatilake, D.; Tiffen, J.C.; Gowrishankar, K.; Jin, L.; Pupo, G.M.; Cullinane, C.; Prinjha, R.K.; Smithers, N.; et al. The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells. J. Investig. Dermatol. 2014, 134, 2795–2805. [Google Scholar] [CrossRef] [Green Version]
- Gallagher, S.J.; Mijatov, B.; Gunatilake, D.; Gowrishankar, K.; Tiffen, J.; James, W.; Jin, L.; Pupo, G.; Cullinane, C.; McArthur, G.; et al. Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. Pigment. Cell Melanoma Res. 2014, 27, 1126–1137. [Google Scholar] [CrossRef]
- Hodis, E.; Watson, I.; Kryukov, G.; Arold, S.T.; Imielinski, M.; Theurillat, J.-P.; Nickerson, E.; Auclair, D.; Li, L.; Place, C.; et al. A landscape of driver mutations in melanoma. Cell 2012, 150, 251–263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qadeer, Z.A.; Harcharik, S.; Valle-Garcia, D.; Chen, C.; Birge, M.B.; Vardabasso, C.; Duarte, L.F.; Bernstein, E. Decreased expression of the chromatin remodeler ATRX associates with melanoma progression. J. Investig. Dermatol. 2014, 134, 1768–1772. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koludrovic, D.; Laurette, P.; Strub, T.; Keime, C.; Le Coz, M.; Coassolo, S.; Mengus, G.; LaRue, L.; Davidson, I. Chromatin-remodelling complex NURF is essential for differentiation of adult melanocyte stem cells. PLoS Genet. 2015, 11, e1005555. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, S.; Tetzlaff, M.T.; Cui, R.; Xu, X. miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am. J. Pathol. 2012, 181, 1823–1835. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Satzger, I.; Mattern, A.; Kuettler, U.; Weinspach, D.; Niebuhr, M.; Kapp, A.; Gutzmer, R. microRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells. Exp. Dermatol. 2012, 21, 509–514. [Google Scholar] [CrossRef]
- Jin, L.; Hu, W.L.; Jiang, C.C.; Wang, J.X.; Han, C.C.; Chu, P.; Zhang, L.J.; Thorne, R.F.; Wilmott, J.; Scolyer, R.A.; et al. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc. Natl. Acad. Sci. USA 2011, 108, 15840–15845. [Google Scholar] [CrossRef] [Green Version]
- Pencheva, N.; Tran, H.; Buss, C.; Huh, D.; Drobnjak, M.; Busam, K.; Tavazoie, S.F. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell 2012, 151, 1068–1082. [Google Scholar] [CrossRef] [Green Version]
- Tang, L.; Zhang, W.; Su, B.; Yu, B. Long noncoding RNA HOTAIR is associated with motility, invasion, and metastatic potential of metastatic melanoma. BioMed Res. Int. 2013, 2013, 1–7. [Google Scholar] [CrossRef] [Green Version]
- Yu, X.; Zheng, H.; Tse, G.; Chan, M.; Wu, W.K. Long non-coding RNAs in melanoma. Cell Prolif. 2018, 51, e12457. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Strub, T.; Ballotti, R.; Bertolotto, C. The “ART” of epigenetics in melanoma: From histone “alterations, to resistance and therapies”. Theranostics 2020, 10, 1777–1797. [Google Scholar] [CrossRef]
- Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128, 693–705. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nguyen, C.T.; Weisenberger, D.J.; Velicescu, M.; A Gonzales, F.; Lin, J.C.Y.; Liang, G.; A Jones, P. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2’-deoxycytidine. Cancer Res. 2002, 62, 6456–6461. [Google Scholar]
- Seligson, D.B.; Horvath, S.; Shi, T.; Yu, H.; Tze, S.; Grunstein, M.; Kurdistani, S. Global histone modification patterns predict risk of prostate cancer recurrence. Nat. Cell Biol. 2005, 435, 1262–1266. [Google Scholar] [CrossRef]
- Ye, Y.; Jin, L.; Wilmott, J.; Hu, W.L.; Yosufi, B.; Thorne, R.F.; Liu, T.; Rizos, H.; Yan, X.G.; Dong, L.; et al. PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nat. Commun. 2013, 4, 1508. [Google Scholar] [CrossRef] [Green Version]
- McHugh, J.B.; Fullen, D.R.; Ma, L.; Kleer, C.G.; Su, L.D. Expression of polycomb group protein EZH2 in nevi and melanoma. J. Cutan. Pathol. 2007, 34, 597–600. [Google Scholar] [CrossRef]
- Hjelmeland, A.B.; Wu, Q.; Heddleston, J.M.; Choudhary, G.S.; MacSwords, J.; Lathia, J.D.; McLendon, R.; Lindner, D.; Sloan, A.; Rich, J.N. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011, 18, 829–840. [Google Scholar] [CrossRef] [Green Version]
- Pang, M.-F.; Siedlik, M.J.; Han, S.; Stallings-Mann, M.; Radisky, D.C.; Nelson, C.M. Tissue stiffness and hypoxia modulate the integrin-linked kinase ILK to control breast cancer stem-like cells. Cancer Res. 2016, 76, 5277–5287. [Google Scholar] [CrossRef] [Green Version]
- Lagadec, C.; Vlashi, E.; Della Donna, L.; Dekmezian, C.; Pajonk, F. Radiation-induced reprogramming of breast cancer cells. Stem Cells 2012, 30, 833–844. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, J.; Molley, T.G.; Seward, C.H.; Abdeen, A.A.; Zhang, H.; Wang, X.; Gandhi, H.; Yang, J.-L.; Gaus, K.; Kilian, K.A. Geometric regulation of histone state directs melanoma reprogramming. Commun. Biol. 2020, 3, 1–9. [Google Scholar] [CrossRef]
- Mashtalir, N.; D’Avino, A.; Michel, B.C.; Luo, J.; Pan, J.; Otto, J.E.; Zullow, H.J.; McKenzie, Z.M.; Kubiak, R.L.; Pierre, R.S.; et al. Modular organization and assembly of SWI/SNF family chromatin remodeling complexes. Cell 2018, 175, 1272–1288.e20. [Google Scholar] [CrossRef] [Green Version]
- Lu, C.; Allis, C.D. SWI/SNF complex in cancer. Nat. Genet. 2017, 49, 178–179. [Google Scholar] [CrossRef] [PubMed]
- Vardabasso, C.; Hasson, D.; Ratnakumar, K.; Chung, C.-Y.; Duarte, L.F.; Bernstein, E. Histone variants: Emerging players in cancer biology. Cell. Mol. Life Sci. 2014, 71, 379–404. [Google Scholar] [CrossRef] [Green Version]
- Zingg, D.; Debbache, J.; Schaefer, S.M.; Tuncer, E.; Frommel, S.C.; Cheng, P.; Arenas-Ramirez, N.; Haeusel, J.; Zhang, Y.; Bonalli, M.; et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat. Commun. 2015, 6, 6051. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kapoor, A.; Goldberg, M.S.; Cumberland, L.K.; Ratnakumar, K.; Segura, M.F.; Emanuel, P.O.; Menendez, S.; Vardabasso, C.; LeRoy, G.; Vidal, C.I.; et al. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nat. Cell Biol. 2010, 468, 1105–1109. [Google Scholar] [CrossRef]
- Vardabasso, C.; Gaspar-Maia, A.; Hasson, D.; Pünzeler, S.; Valle-Garcia, D.; Straub, T.; Keilhauer, E.C.; Strub, T.; Dong, J.; Panda, T.; et al. Histone variant H2A.Z.2 mediates proliferation and drug sensitivity of malignant melanoma. Mol. Cell 2015, 59, 75–88. [Google Scholar] [CrossRef] [Green Version]
- Costa, F.F. Non-coding RNAs: Lost in translation? Gene 2007, 386, 1–10. [Google Scholar] [CrossRef]
- Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215–233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wapinski, O.; Chang, H.Y. Long noncoding RNAs and human disease. Trends Cell Biol. 2011, 21, 354–361. [Google Scholar] [CrossRef]
- Streicher, K.L.; Zhu, W.; Lehmann, K.P.; Georgantas, R.W.; Morehouse, C.A.; Brohawn, P.; Carrasco, R.A.; Xiao, Z.; Tice, D.A.; Higgs, B.W.; et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene 2012, 31, 1558–1570. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gajos-Michniewicz, A.; Czyz, M. Role of miRNAs in melanoma metastasis. Cancers 2019, 11, 326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prachayasittikul, V.; Prathipati, P.; Pratiwi, R.; Phanus-Umporn, C.; Malik, A.A.; Schaduangrat, N.; Seenprachawong, K.; Wongchitrat, P.; Supokawej, A.; Prachayasittikul, V.; et al. Exploring the epigenetic drug discovery landscape. Expert Opin. Drug Discov. 2017, 12, 345–362. [Google Scholar] [CrossRef] [PubMed]
- Cheng, Y.; He, C.; Wang, M.; Ma, X.; Mo, F.; Yang, S.; Han, J.; Wei, X. Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduct. Target. Ther. 2019, 4, 1–39. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Woods, D.M.; Woan, K.; Cheng, F.; Wang, H.; Perez-Villarroel, P.; Lee, C.; Lienlaf, M.; Atadja, P.; Seto, E.; Weber, J.; et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 2013, 23, 341–348. [Google Scholar] [CrossRef] [Green Version]
- McMillan, T.J.; Hart, I.R. Enhanced experimental metastatic capacity of a murine melanoma following pre-treatment with anticancer drugs. Clin. Exp. Metastasis 1986, 4, 285–292. [Google Scholar] [CrossRef]
- Rollins, R.A.; Kim, K.H.; Tsao, C.-C. The emerging epigenetic landscape in melanoma. In Human Skin Cancer, Potential Biomarkers and Therapeutic Targets; IntechOpen: London, UK, 2016. [Google Scholar]
- Cossío, F.P.; Esteller, M.; Berdasco, M. Towards a more precise therapy in cancer: Exploring epigenetic complexity. Curr. Opin. Chem. Biol. 2020, 57, 41–49. [Google Scholar] [CrossRef]
- Ottaviano, M.; De Placido, S.; Ascierto, P.A. Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma. Virchows Archiv 2019, 474, 421–432. [Google Scholar] [CrossRef]
- Gide, T.N.; Wilmott, J.S.; Scolyer, R.A.; Long, G.V. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin. Cancer Res. 2018, 24, 1260–1270. [Google Scholar] [CrossRef] [Green Version]
- Karantanos, T.; Christofides, A.; Bardhan, K.; Li, L.; Boussiotis, V.A. Regulation of T cell differentiation and function by EZH2. Front. Immunol. 2016, 7, 172. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Manning, C.; Hooper, S.J.; A Sahai, E. Intravital imaging of SRF and Notch signalling identifies a key role for EZH2 in invasive melanoma cells. Oncogene 2015, 34, 4320–4332. [Google Scholar] [CrossRef] [Green Version]
- Zingg, D.; Arenas-Ramirez, N.; Sahin, D.; Rosalia, R.A.; Antunes, A.T.; Haeusel, J.; Sommer, L.; Boyman, O. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 2017, 20, 854–867. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sheng, W.; LaFleur, M.; Nguyen, T.; Chen, S.; Chakravarthy, A.; Conway, J.; Li, Y.; Chen, H.; Yang, H.; Hsu, P.-H.; et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell 2018, 174, 549–563.e19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pan, D.; Kobayashi, A.; Jiang, P.; De Andrade, L.F.; Tay, R.E.; Luoma, A.M.; Tsoucas, D.; Qiu, X.; Lim, K.; Rao, P.; et al. A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing. Science 2018, 359, 770–775. [Google Scholar] [CrossRef] [Green Version]
- Covre, A.; Coral, S.; Nicolay, H.; Parisi, G.; Fazio, C.; Colizzi, F.; Fratta, E.; Di Giacomo, A.M.; Sigalotti, L.; Natali, P.G.; et al. Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. OncoImmunology 2015, 4, e1019978. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vo, D.D.; Prins, R.; Begley, J.L.; Donahue, T.R.; Morris, L.F.; Bruhn, K.W.; De La Rocha, P.; Yang, M.-Y.; Mok, S.; Garban, H.; et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009, 69, 8693–8699. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hamm, S.; Wulff, T.; Kronthaler, K.; Schrepfer, S.; Parnitzke, U.; Bretz, A.C.; Bartz, R. Abstract 4722: 4SC-202 increases immunogenicity of tumor cells, induces infiltration of tumor microenvironment with cytotoxic T cells, and primes tumors for combinations with different cancer immunotherapy approaches. Immunology 2018, 78, 4722. [Google Scholar] [CrossRef]
- Khushalani, N.I.; Markowitz, J.; Eroglu, Z.; Giuroiu, I.; Ladanova, V.; Reiersen, P.; Rich, J.; Thapa, R.; Schell, M.J.; Sotomayor, E.M.; et al. A phase I trial of panobinostat with ipilimumab in advanced melanoma. J. Clin. Oncol. 2017, 35, 9547. [Google Scholar] [CrossRef]
- Hassel, J.; Berking, C.; Eigentler, T.; Gutzmer, R.; Ascierto, P.; Schilling, B.; Hermann, F.; Bartz, R.; Schadendorf, D. Phase Ib/II study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy. Ann. Oncol. 2019, 30, v559. [Google Scholar] [CrossRef]
- Efficacy and Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in Patients with Melanoma Previously Treated with Anti-PD1 Therapy. Available online: https://www.abstractsonline.com/pp8/#!/6812/presentation/9829 (accessed on 16 June 2021).
- Echevarría-Vargas, I.M.; I Reyes-Uribe, P.; Guterres, A.; Yin, X.; Kossenkov, A.V.; Liu, Q.; Zhang, G.; Krepler, C.; Cheng, C.; Wei, Z.; et al. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol. Med. 2018, 10, e8446. [Google Scholar] [CrossRef] [Green Version]
- Maertens, O.; Kuzmickas, R.; Manchester, H.E.; Emerson, C.E.; Gavin, A.G.; Guild, C.J.; Wong, T.C.; De Raedt, T.; Bowman-Colin, C.; Hatchi, E.; et al. MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF-, NRAS-, and NF1-mutant melanomas. Cancer Discov. 2019, 9, 526–545. [Google Scholar] [CrossRef] [Green Version]
- Zakharia, Y.; Monga, V.; Swami, U.; Bossler, A.; Freesmeier, M.; Frees, M.; Khan, M.; Frydenlund, N.; Srikantha, R.; Vanneste, M.; et al. Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study. Oncotarget 2017, 8, 89182–89193. [Google Scholar] [CrossRef] [Green Version]
- Tawbi, H.A.; Beumer, J.; Tarhini, A.A.; Moschos, S.; Buch, S.C.; Egorin, M.J.; Lin, Y.; Christner, S.; Kirkwood, J.M. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: A phase I/II study and pharmacokinetic analysis. Ann. Oncol. 2013, 24, 1112–1119. [Google Scholar] [CrossRef]
- Daud, A.I.; Dawson, J.; DeConti, R.C.; Bicaku, E.; Marchion, D.; Bastien, S.; Hausheer, F.A.; Lush, R.; Neuger, A.; Sullivan, D.M.; et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: Translational and phase I/II clinical trial. Clin. Cancer Res. 2009, 15, 2479–2487. [Google Scholar] [CrossRef] [Green Version]
- Ottaviano, M.; Giunta, E.; Tortora, M.; Curvietto, M.; Attademo, L.; Bosso, D.; Cardalesi, C.; Rosanova, M.; De Placido, P.; Pietroluongo, E.; et al. BRAF gene and melanoma: Back to the future. Int. J. Mol. Sci. 2021, 22, 3474. [Google Scholar] [CrossRef]
- Hugo, W.; Shi, H.; Sun, L.; Piva, M.; Song, C.; Kong, X.; Moriceau, G.; Hong, A.; Dahlman, K.B.; Johnson, D.B.; et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 2015, 162, 1271–1285. [Google Scholar] [CrossRef] [Green Version]
- Valpione, S.; Carlino, M.S.; Mangana, J.; Mooradian, M.J.; McArthur, G.; Schadendorf, D.; Hauschild, A.; Menzies, A.; Arance, A.; Ascierto, P.A.; et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. Eur. J. Cancer 2018, 91, 116–124. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, C.; Tian, C.; Hoffman, T.E.; Jacobsen, N.K.; Spencer, S.L. Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling. Nat. Commun. 2021, 12, 1–14. [Google Scholar] [CrossRef]
- Khaliq, M.; Fallahi-Sichani, M. Epigenetic mechanisms of escape from BRAF oncogene dependency. Cancers 2019, 11, 1480. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khaliq, M.; Manikkam, M.; Martinez, E.D.; Fallahi-Sichani, M. Epigenetic modulation reveals differentiation state specificity of oncogene addiction. Nat. Commun. 2021, 12, 1–15. [Google Scholar] [CrossRef] [PubMed]
- Al Emran, A.; Marzese, D.M.; Menon, D.R.; Stark, M.; Torrano, J.; Hammerlindl, H.; Zhang, G.; Brafford, P.; Salomon, M.P.; Nelson, N.; et al. Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget 2018, 9, 8206–8222. [Google Scholar] [CrossRef] [Green Version]
- Roesch, A.; Vultur, A.; Bogeski, I.; Wang, H.; Zimmermann, K.M.; Speicher, D.; Körbel, C.; Laschke, M.W.; Gimotty, P.A.; Philipp, S.E.; et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells. Cancer Cell 2013, 23, 811–825. [Google Scholar] [CrossRef] [Green Version]
- Menon, D.R.; Das, S.; Krepler, C.; Vultur, A.; Rinner, B.; Schauer, S.; Kashofer, K.; Wagner, K.; Zhang, G.; Rad, E.B.; et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene 2015, 34, 4448–4459. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Strub, T.; Ghiraldini, F.G.; Carcamo, S.; Li, M.; Wroblewska, A.; Singh, R.; Goldberg, M.S.; Hasson, D.; Wang, Z.; Gallagher, S.; et al. SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling. Nat. Commun. 2018, 9, 1–13. [Google Scholar] [CrossRef]
- Zanconato, F.; Battilana, G.; Forcato, M.; Filippi, L.; Azzolin, L.; Manfrin, A.; Quaranta, E.; Di Biagio, D.; Sigismondo, G.; Guzzardo, V.; et al. Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4. Nat. Med. 2018, 24, 1599–1610. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; de Oliveira, R.L.; Huijberts, S.; Bosdriesz, E.; Pencheva, N.; Brunen, D.; Bosma, A.; Song, J.-Y.; Zevenhoven, J.; Vries, T.L.-D.; et al. An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential. Cell 2018, 173, 1413–1425.e14. [Google Scholar] [CrossRef] [Green Version]
- Yu, Y.; Schleich, K.; Yue, B.; Ji, S.; Lohneis, P.; Kemper, K.; Silvis, M.R.; Qutob, N.; Van Rooijen, E.; Werner-Klein, M.; et al. Targeting the senescence-overriding cooperative activity of structurally unrelated H3K9 demethylases in melanoma. Cancer Cell 2018, 33, 322–336.e8. [Google Scholar] [CrossRef] [Green Version]
- Perotti, V.; Baldassari, P.; Molla, A.; Nicolini, G.; Bersani, I.; Grazia, G.; Benigni, F.; Maurichi, A.; Santinami, M.; Anichini, A.; et al. An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells. Oncogene 2019, 38, 4384–4396. [Google Scholar] [CrossRef] [PubMed]
- Palumbo, G.; Di Lorenzo, G.; Ottaviano, M.; Damiano, V. The future of melanoma therapy: Developing new drugs and improving the use of old ones. Futur. Oncol. 2016, 12, 2531–2534. [Google Scholar] [CrossRef] [PubMed]
- Xia, C.; Leon-Ferre, R.; Laux, D.; Deutsch, J.; Smith, B.J.; Frees, M.; Milhem, M. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Cancer Chemother. Pharmacol. 2014, 74, 691–697. [Google Scholar] [CrossRef] [Green Version]
- Valentini, A.; Gravina, P.; Federici, G.; Bernardini, S. Valproic acid induces apoptosis, p16INK4 Aupregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol. Ther. 2007, 6, 185–191. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fulda, S.; Küfer, M.U.; Meyer, E.; Van Valen, F.; Dockhorn-Dworniczak, B.; Debatin, K.-M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001, 20, 5865–5877. [Google Scholar] [CrossRef] [Green Version]
- Soengas, M.; Capodieci, P.; Polsky, D.; Mora, J.; Esteller, M.; Opitz-Araya, X.; McCombie, W.R.; Herman, J.G.; Gerald, W.L.; Lazebnik, Y.A.; et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nat. Cell Biol. 2001, 409, 207–211. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.-G.; Park, M.-T.; Heo, K.; Yang, K.-M.; Yi, J.M. Epigenetics meets radiation biology as a new approach in cancer treatment. Int. J. Mol. Sci. 2013, 14, 15059–15073. [Google Scholar] [CrossRef] [Green Version]
- Munshi, A.; Kurland, J.F.; Nishikawa, T.; Tanaka, T.; Hobbs, M.L.; Tucker, S.L.; Ismail, S.; Stevens, C.; Meyn, R.E. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 2005, 11, 4912–4922. [Google Scholar] [CrossRef] [Green Version]
- Munshi, A.; Tanaka, T.; Hobbs, M.L.; Tucker, S.L.; Richon, V.M.; Meyn, R.E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci. Mol. Cancer Ther. 2006, 5, 1967–1974. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rieth, J.; Swami, U.; Mott, S.; Zanaty, M.; Henry, M.; Bossler, A.; Greenlee, J.; Zakharia, Y.; Vanneste, M.; Jennings, B.; et al. Melanoma brain metastases in the era of targeted therapy and checkpoint inhibitor therapy. Cancers 2021, 13, 1489. [Google Scholar] [CrossRef]
- Marzese, D.M.; Scolyer, R.A.; Roqué, M.; Vargas-Roig, L.M.; Huynh, J.L.; Wilmott, J.; Murali, R.; Buckland, M.E.; Barkhoudarian, G.; Thompson, J.; et al. DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology 2014, 16, 1499–1509. [Google Scholar] [CrossRef] [Green Version]
- Orozco, J.I.J.; Knijnenburg, T.A.; Manughian-Peter, A.; Salomon, M.P.; Barkhoudarian, G.; Jalas, J.R.; Wilmott, J.; Hothi, P.; Wang, X.; Takasumi, Y.; et al. Epigenetic profiling for the molecular classification of metastatic brain tumors. Nat. Commun. 2018, 9, 1–14. [Google Scholar] [CrossRef]
- Yang, Y.; Wang, Y. Role of epigenetic regulation in plasticity of tumor immune microenvironment. Front. Immunol. 2021, 12, 1013. [Google Scholar] [CrossRef]
- Mitra, S.; Lauss, M.; Cabrita, R.; Choi, J.; Zhang, T.; Isaksson, K.; Olsson, H.; Ingvar, C.; Carneiro, A.; Staaf, J.; et al. Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma. Mol. Oncol. 2020, 14, 933–950. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Class of Epigenetic Alteration | Type of Epigenetic Alteration | Involved Gene(s) | Evidence in Melanoma | Ref |
---|---|---|---|---|
DNA Methylation status modification | Promoter methylation | PTEN | Up to 60% of melanoma serum samples Independent poor prognostic factor | [24,25] |
CDKN2A | Up to 25% of melanoma tissue samples Cell cycle deregulation | [26,27,28] | ||
ARF | Up to 60% of melanoma tissue samples Cell cycle deregulation | [30] | ||
Gene methylation | RASSF1A | Up to 55% of melanoma tissue samples | [31] | |
cGAS and STING | Resistance to T-cell-based anticancer therapies | [37] | ||
Gene hypomethylation | IDH-2 (?) | Disruption of TET ability to maintain DNA methylation fidelity | [43] | |
Chromatin remodeling perturbation | Histone hypoacetylation | Bcl2 | Downregulation of antiapoptotic members | [45] |
Histone hypermethylation | EZH2 | High proliferation rate and aggressive tumor subgroups | [46] | |
SETDB1 | Acceleration of melanoma onset | [47] | ||
EHMT2 | Up to 25% of melanoma tissue samples | [48] | ||
KMT2D | Participation to melanomagenesis | [49] | ||
JARID1B | Tumor growth and intrinsic drug resistance | [50] | ||
Chromatin modification recognition | BRD2 and BRD4 | Apoptosis inhibition and cell cycle deregulation | [51,52,53] | |
SWI/SNF complex regulation | ARID1A, ARID1B, ARID2, and SMARCA4 | Loss of ability to repair DNA double strand breaks and UV-induced pyrimidine dimers | [54] | |
ATRX | Melanoma progression | [55] | ||
NURF complex regulation | BPTF | Disruption of gene expression programs | [56] | |
Non-coding RNA regulation | miRNA | MiR-200c | Reduced expression of adhesion molecules | [57] |
MiR-149 and MiR-21 | Apoptosis inhibition | [58,59] | ||
MiR-1908, miR-199a-5p, and miR-199a-3p | Promotion of invasion and metastasis formation Shorter overall survival | [60] | ||
lncRNA | HOTAIR | Alteration of chromatin structure | [61] | |
MALAT1 | Apoptosis inhibition, promotion of invasion and metastasis formation | [62] |
Class of Therapeutic Partner | Partner Drug | Epigenetic Drug | Evidence in Melanoma | Ref |
---|---|---|---|---|
Immunotherapy | 9H10 (anti-CTLA-4 antibody) | 5-aza-2′-deoxycytidine (DNA hypomethylating agent) | Significant immune-related antitumor activity in syngeneic transplantable murine models | [97] |
Gp100 melanoma antigen-specific pmel-1 T-cells (adoptive transfer) | LAQ824 (HDACi) | Improvement of antitumor activity in murine models | [98] | |
Ipilimumab (anti-CTLA-4 antibody) | Panobinostat (pan-HDACi) | Phase I clinical trial: not increased responses in advanced melanoma patients respect to single-agent ipilimumab | [100] | |
SGI-110: precursor of decitabine (DNMTi) | Phase 1 clinical trial (ongoing) | NCT02608437 | ||
Pembrolizumab (anti-PD-1 antibody) | Domatinostat (class I HDACi) | Phase Ib/II clinical trial (SENSITIZE): safety and tolerability of combination and potential increase in antitumor activity in pretreated melanoma patients | [101] | |
Entinostat (class I HDACi) | Ph1b/2 Dose-Escalation Study (ENCORE 601) of Entinostat with Pembrolizumab in NSCLC with Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer | [102] | ||
Entinostat (class I HDACi) | Phase II clinical trial (ongoing) | NCT03765229 | ||
Azacytidine | Phase II clinical trial (ongoing) | NCT02816021 | ||
Nivolumab (anti-PD-1 antibody) | Tinostamustine: fusion molecule of bendamustine (alkylating agent) + vorinostat (pan-HDACi) | Phase I clinical trial (ongoing) | NCT03903458 | |
Ipilimumab (anti-CTLA-4 antibody) + nivolumab (anti-PD-1 antibody) | ACY-241 (HDAC6 inhibitor) | Phase I clinical trial (ongoing) | NCT02935790 | |
Targeted therapy | PD901 (MEK inhibitor) | JQ-1 (BET inhibitor) | Reversion of therapeutic resistance in preclinical models | [103] |
Dabrafenib (BRAF inhibitor) + trametinib (MEK inhibitor) | Vorinostat (pan-HDACi) | Enhancement of tumor regression | [104] | |
Vemurafenib (BRAF inhibitor) | Decitabine (DNMTi) | Phase I clinical trial (interrupted) | [105] | |
Chemotherapy | Temozolomide (alkylating agent) | Decitabine (DNMTi) | Phase I/II clinical trial | [106] |
Karenitecin (topoisomerase 1 inhibitor) | Valproic acid (HDACi) | Translational study Phase I/II clinical trial | [107] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Giunta, E.F.; Arrichiello, G.; Curvietto, M.; Pappalardo, A.; Bosso, D.; Rosanova, M.; Diana, A.; Giordano, P.; Petrillo, A.; Federico, P.; et al. Epigenetic Regulation in Melanoma: Facts and Hopes. Cells 2021, 10, 2048. https://doi.org/10.3390/cells10082048
Giunta EF, Arrichiello G, Curvietto M, Pappalardo A, Bosso D, Rosanova M, Diana A, Giordano P, Petrillo A, Federico P, et al. Epigenetic Regulation in Melanoma: Facts and Hopes. Cells. 2021; 10(8):2048. https://doi.org/10.3390/cells10082048
Chicago/Turabian StyleGiunta, Emilio Francesco, Gianluca Arrichiello, Marcello Curvietto, Annalisa Pappalardo, Davide Bosso, Mario Rosanova, Anna Diana, Pasqualina Giordano, Angelica Petrillo, Piera Federico, and et al. 2021. "Epigenetic Regulation in Melanoma: Facts and Hopes" Cells 10, no. 8: 2048. https://doi.org/10.3390/cells10082048